- iSpecimen Inc (NASDAQ:ISPC) has added new global biospecimen suppliers to its proprietary Marketplace platform for advancing oncology and cardiovascular disease research.
- The new suppliers include a cancer-focused biobank in the U.S., which contains a differentiated range of pre-and post-treatment tissue and biofluids across multiple cancer types.
- These samples provide rich genetic, treatment, follow-up, and outcome information.
- Additionally, iSpecimen has retained a European biobank with a vast urine and blood sample inventory from healthy participants aged 45 to 75, collected with participant health data generated from questionnaires and disease diagnoses.
- This biobank contains vital early-onset cancer and cardiovascular disease samples, as well.
- iSpecimen offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers with access to patients and specimens needed for medical discovery.
- Price Action: ISPC shares are up 21.50% at $2.88 during the market session on the last check Thursday.
22nd Century Group Stock (XXII) Is Down 45%: What’s Going On?
22nd Century Group shares are trading lower by 45% to $1.96 during Monday's session. The stock is potentially trading lower likely due to profit-taking following a new contract announced last week.
